Core Insights - Samsung Biologics has achieved the EcoVadis Platinum Sustainability Rating, the highest recognition for corporate sustainability performance, placing it in the top one percent of evaluated companies globally [1][2][10] Sustainability Performance - The EcoVadis rating evaluates corporate social responsibility across four areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement [2] - Samsung Biologics was previously awarded the Gold Sustainability Rating in 2024, indicating a consistent improvement in sustainability practices [3] Management Commitment - John Rim, President and CEO, emphasized the company's commitment to responsible business practices and long-term partnerships that contribute to a sustainable healthcare ecosystem [4] - The company has enhanced sustainability initiatives, including increased use of renewable energy and improved ethical compliance frameworks [4] Industry Engagement - Samsung Biologics received an 'A' rating in Water Security from the Carbon Disclosure Project (CDP) in December 2025 [4] - As a Champion of the Sustainable Markets Initiative Health Systems Task Force, the company engages global suppliers in decarbonization efforts [4] Manufacturing Capacity - Samsung Biologics has a combined biomanufacturing capacity of 785,000 liters, with an additional 60,000 liters expected from a facility acquisition in Rockville, Maryland, by the end of Q1 2026 [7] - The company utilizes advanced technologies for various biopharmaceutical modalities, including multispecific antibodies and mRNA therapeutics [7] Operational Excellence - The ExellenSâ"¢ framework is implemented across the manufacturing network to ensure standardized designs and processes, enhancing manufacturing continuity [8] - The global manufacturing network includes operations in Korea, the U.S., and Japan, with a focus on delivering high-quality biomedicines [9]

Core Insights - Samsung Biologics has achieved an 'A' rating in Water Security from the Carbon Disclosure Project (CDP), marking a significant improvement from the previous year [1][2] - The CDP 'A List' recognizes companies that demonstrate exceptional leadership in environmental stewardship, with only about 2% of participating companies receiving this distinction [2][3] Company Achievements - Samsung Biologics has been participating in CDP assessments for two years and has improved its rating by one level, reflecting its commitment to sustainability [2] - The company was acknowledged for setting concrete goals in natural capital strategies, water pollution management, and water reuse rates, along with high accuracy in reporting water-related data [4] Strategic Goals - The CEO of Samsung Biologics emphasized the company's ongoing commitment to align with global ESG strategies and aims for carbon neutrality while enhancing water resource management [4] - Samsung Biologics is a champion of the Supply Chains Working Group within the Sustainable Markets Initiative (SMI) Health Systems Task Force, reinforcing its role as a sustainable CDMO partner [4] Operational Capacity - Samsung Biologics operates with a biomanufacturing capacity of 784,000 liters across five plants, utilizing advanced technologies for various biopharmaceutical modalities [5] - The company implements the ExellenSâ"¢ framework to ensure manufacturing continuity and operational excellence across its facilities [6] Commitment to Sustainability - Samsung Biologics is focused on transitioning to renewable energy by 2050 and aims to manage natural capital while reducing climate impact throughout its value chain [4][7] - The company is dedicated to delivering safe, high-quality products on time and in full, while making sustainable business decisions for societal and global health benefits [7]